Introducing the HLA Assay as a Companion Diagnostic in Immunotherapy Development Webinar
Watch this on-demand webinar that discusses the critical role of human leukocyte antigen (HLA) genes in immunotherapy. This webinar explores the significance of HLA molecules in presenting tumor-specific antigens to T cell receptors (TCR) to eliminate tumor cells.
In this webinar, Dr. Sean Carey, the Senior Manager of Scientific Affairs at Thermo Fisher Scientific, provides an in-depth overview of the importance of HLA genes in the adoptive immune response. He highlights how HLA molecules play a crucial role in the immune system's ability to recognize and eliminate cancer cells.
Moreover, we are joined by Lee-Anne Zinetti, the Senior Director of Global Lead Precision Medicine at Novartis, who discusses the benefits and importance of codeveloping a companion diagnostic (CDx) for precision medicine from the early stages of drug development. The webinar covers the challenges and regulatory requirements associated with the development of a CDx, and how codevelopment can prevent delays and reduce the overall cost of therapy.
Viewers can gain a comprehensive understanding of the importance of HLA molecules in cancer immunotherapy, along with the significance and benefits of developing a CDx. This webinar was designed for scientists, researchers, clinicians, and anyone interested in the latest developments in cancer immunotherapy. Watch it now to learn from leading experts and gain invaluable insights into this
critical area.
Learning Objectives:
- Get an introduction to HLA
- Discover how HLA is involved in immunotherapy
- Understand a workflow for developing a CDx
Share This Page
Speakers:
Dr. Sean Carey
Senior Manager, Scientific Affairs,
Thermo Fisher Scientific
Lee-Anne Zinetti
Senior Director,
Global Lead Precision Medicine,
Novartis
Recorded:
May 15, 2023
Guest Speakers:
Sean Carey
Sean Carey, DClinSci, ESHI, FRCPath.
Senior Manager, Scientific Affairs
Thermo Fisher Scientific
Sean Carey is the Scientific Affairs Senior Manager for the Transplant Diagnostics (TDx) section of Thermo Fisher Scientific.
Before taking this post in May 2022, Dr. Carey was the Consultant Clinical Scientist responsible for the Histocompatibility and Immunogenetics (H&I) laboratory at University Hospitals Plymouth (UHP), UK.
His career in the transplantation laboratory began at Guy’s Hospital, London, in 1992 where he was employed to investigate the efficacy of immunosuppressant drugs, and the immunological desensitization of highly sensitized renal patients. Dr. Carey moved into the routine transplant laboratory at Guy’s in 1996 and completed his master’s in immunology the following year.
Taking the role of Chief Biomedical Scientist at UHP in 2002, he implemented flow cytometric crossmatching and led the team to introduce One Lambda’s suite of Luminex tests. Following a few years in senior laboratory management, Dr. Carey focused his attention back on transplantation in 2014 as Lead Healthcare Scientist in H&I at UHP, commencing a doctorate course with the University of Manchester at the same time. He achieved Doctor of Clinical Science (DCLinSci) in 2020 and was admitted as a Fellow of the Royal College of Pathologists the same year, having completed the examinations during his doctorate.
Dr. Carey has published extensively throughout his career, beginning with a first author paper in 1992. His doctorate research led to three first author publications, including a review of HLA expression in 2019, which has been cited almost 50 times to date.
Dr. Sean Carey
Senior Manager, Scientific Affairs
Thermo Fisher Scientific
Lee-Anne Zinetti
Lee-Anne Zinetti
Senior Director, Global Lead Precision Medicine
Novartis
Lee-Anne Zinetti has worked in the field of molecular diagnostics for 18 years with a focus on oncology and companion diagnostics. Her role is focused on driving the uptake of quality diagnostic testing so that all patients eligible will have access to the right drug at the right time. With the varying levels of adoption and reimbursement of biomarker testing globally ensuring global testing access means working across multiple technology platforms including NGS, IHC, qPCR, and liquid biopsy.
Zinetti is also board member at From Testing to Targeted Treatment Program (FT3), a multi-stakeholder collaborative program that aims to unify, accelerate, and build on existing efforts to make precision medicine a reality for all patients who could benefit from it. Co-led by patients, FT3 is strongly focused on patient needs and experiences.
Lee-Anne Zinetti
Senior Director, Global Lead Precision Medicine
Novartis
